These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8286745)

  • 41. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
    Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
    Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The toxicity of chemically deglycosylated ricin A-chain in mice.
    Soler-Rodriguez AM; Uhr JW; Richardson J; Vitetta ES
    Int J Immunopharmacol; 1992 Feb; 14(2):281-91. PubMed ID: 1624227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
    Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A.
    Barnett MJ; Rohatiner AZ; Kingston JE; Adams KE; Batten EL; Bassan R; Thorpe PE; Horton MA; Malpas JS; Lister TA
    Haematol Blood Transfus; 1987; 31():57-8. PubMed ID: 3327786
    [No Abstract]   [Full Text] [Related]  

  • 49. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.
    Liu C; Lambert JM; Teicher BA; Blättler WA; O'Connor R
    Blood; 1996 May; 87(9):3892-8. PubMed ID: 8611717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
    Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
    Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
    Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
    Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
    Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
    Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
    Kapp U; Düx A; Schell-Frederick E; Banik N; Hummel M; Mücke S; Fonatsch C; Bullerdiek J; Gottstein C; Engert A
    Ann Oncol; 1994; 5 Suppl 1():121-6. PubMed ID: 7513537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
    Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
    Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
    Stone MJ; Sausville EA; Fay JW; Headlee D; Collins RH; Figg WD; Stetler-Stevenson M; Jain V; Jaffe ES; Solomon D; Lush RM; Senderowicz A; Ghetie V; Schindler J; Uhr JW; Vitetta ES
    Blood; 1996 Aug; 88(4):1188-97. PubMed ID: 8695836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.